GlobeNewswire·Aug 12, 2026, 4:05 PM ET

RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth

RenovoRx raised its 2026 annual revenue guidance to a range of $3.75 million to $4.25 million.
The company reported second quarter 2026 revenue of $909,000, an increase of approximately 61% from Q1 2026 & 115% from Q2 2025.
RenovoRx delivered the first treatment with RenovoCath for a sarcoma patient, expanding the device's use beyond locally advanced pancreatic cancer.
The Phase III TIGeR-PaC trial reached full enrollment, with completion expected in the first half of 2027 & topline data readout in the second half of 2027.
Active commercial cancer center customers increased to 21 in Q2 2026, up from 16 in Q1, with a total commercial pipeline of 63 centers.
The company aims to reach or exceed 36 active commercial cancer center customers by the end of 2026.
RenovoRx expects Q3 2026 revenue to surpass the Q2 record, driven by more active centers & increased repeat ordering.
Gross margin for the quarter was approximately 84%, consistent with the first quarter of 2026.
Net loss for the three months ended June 30, 2026, was approximately $2.9 million, or $0.06 per share.
Cash & cash equivalents stood at approximately $9.5 million as of June 30, 2026.
Management anticipates achieving cash-flow break-even operations in the fourth quarter of 2027.
RenovoRx received FDA Orphan Drug Designation for oxaliplatin in the treatment of pancreatic cancer.
The company plans to host a conference call on August 12, 2026, at 4:30 p.m. ET to discuss results.